Tempus Reports Third Quarter 2026 Results

Tempus AI reported a record $411.5 million in revenue for the quarter ended September 30, 2026. CEO Eric Lefkofsky cited 32% unit growth in oncology and 33% revenue growth in Data & Applications.

Analysis

The useful signal is that growth appears to have two engines—oncology activity and Data & Applications—rather than relying solely on one. If the latter reflects repeatable pharma or provider demand, it could improve revenue visibility and make Tempus less dependent on test volumes; if it is project-based or requires heavy data curation, the reported growth may not translate into durable margins. The release excerpt does not provide gross margin, cash conversion, segment contribution, guidance, or the composition and recurrence of data revenue, so it is not enough to underwrite that distinction.

Near term, a positive growth headline can support TEM, but the market reaction is likely to depend on the omitted profitability and outlook details. Over 1–3 months, verify whether oncology unit growth persists and whether Data & Applications growth converts to gross-profit dollars. Over 6–18 months, a scaled, usable oncology dataset could strengthen Tempus’s negotiating position with life-sciences customers; it could also intensify competition for data partnerships and raise privacy, consent, and execution risks. Oncology diagnostics and data peers may face greater pressure to demonstrate differentiated datasets, but the excerpt does not establish displacement.

Contrarian read: the headline growth rates may overstate economic quality if mix shifts toward lower-contribution work or acquisition/contract timing. Falsifiers of a bullish thesis include slowing oncology units, weaker data growth, deteriorating gross profit or cash conversion, or cautious guidance in the full filing. The excerpt is incomplete; no valuation or consensus comparison is supportable from the supplied information.

Key Decisions for Investors

• Do not chase TEM solely on the headline. Review the complete release and filing for segment gross profit, cash flow, guidance, and whether Data & Applications revenue is recurring before adding exposure.
• For existing positions, retain a constructive but conditional bias; set a review trigger on the next quarterly report if oncology unit growth materially decelerates or Data & Applications growth fails to produce improving gross-profit dollars.
• Watch oncology diagnostics and data competitors for signs of lost partnerships or pricing pressure, but avoid a peer short until customer wins, share shifts, or pricing evidence confirm displacement.
• If the full report validates recurring data revenue and improving cash conversion without weaker guidance, consider staged TEM exposure rather than a single-event trade; otherwise remain on watch pending evidence.